Skip to content
OpenCapital
Get started

Dyne Therapeutics, Inc. DYN Proceeds From Vendor Financing Arrangement

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept dyn:ProceedsFromVendorFinancingArrangement.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Dyne Therapeutics, Inc.'s proceeds from vendor financing arrangement?
Dyne Therapeutics, Inc. (DYN) reported proceeds from vendor financing arrangement of $6.79M in Q1 2026.